This is a two-phase study designed to assess measures of feasibility, sustainability, acceptability, penetration, and fidelity before and after implementation of a rapid molecular HIV-1 viral load testing infrastructure at a level III health center in rural western Uganda. The central hypothesis is that implementation of PoC HIV-1 testing without accompanying modifications to clinic triage and flow, laboratory processes, and existing protocols guiding adherence counseling and regimen change, will not result in significant improvement in clinical outcomes in PLWH.
This is a two-phase study designed to assess measures of feasibility, sustainability, acceptability, penetration, and fidelity before and after implementation of a rapid molecular HIV-1 viral load testing infrastructure at a level III health center in rural western Uganda. In Phase 1, the study team will perform/record the following: 1. Administer a basic demographic and health questionnaire 2. Record routine clinical parameters during visit to include: 1. Current ARV and prophylaxis regimen 2. Last CD4 and VL, if available 3. Clinical illness since last visit 3. Document the amount of time each patient spends in each phase of clinic (i.e. waiting room, provider, phlebotomy, waiting for results, adherence counseling). 4. Measure the number of participants requiring HIV-1 VL testing each clinic day, proportion electing to receive results by phone or at next visit. 5. Patients having blood drawn for HIV-1 VL testing will complete a semi-structured interview to explore perceptions of the current testing paradigm when results are received. 6. Provider and laboratory staff will complete a semi-structured interview to explore perceptions of the current testing paradigm with emphasis on workload In Phase 2, the study team will perform/record the following: 1. Record routine clinical parameters during visit to include: 1. Current ARV and prophylaxis regimen 2. Last CD4 and VL, if available 3. Clinical illness since last visit 2. Determine the amount of time each patient spends in each phase of clinic (i.e. waiting room, provider, phlebotomy, waiting for results, adherence counseling). 3. Measure the number of Xpert HIV-1 tests performed, the amount of time laboratory staff spends performing the tests and conducting maintenance, the number of tests failures and/or invalid tests, and equipment downtime related problems with software or power supply. 4. Measure the number of participants requiring HIV-1 VL testing each clinic day, proportion electing to receive results on same day, by phone, or next visit. 5. Patients having blood drawn for HIV-1 VL testing will complete a semi-structured interview to explore perceptions of the current testing paradigm when results are received. 6. Provider and laboratory staff will complete a semi-structured interview to explore perceptions of the current testing paradigm with emphasis on workload.
Study Type
OBSERVATIONAL
Enrollment
242
Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling
Bugoye Level III Health Centre
Bugoye, Kasese, Uganda
Mbarara University of Science and Technology (MUST)
Mbarara, Uganda
Number of Tests Performed Successfully Each Clinic Day
HIV viral load tests performed at peripheral health center
Time frame: Each clinic day for up to six months
Number of Tests Performed Successfully each Month
HIV viral load tests performed at peripheral health center
Time frame: Each month for up to six months
Proportion of Eligible Patients Electing to Stay to Receive Results
Acceptability of rapid HIV viral load results
Time frame: Each clinic day for up to six months
Proportion of Eligible Patients Electing to Stay to Receive Results
Acceptability of rapid HIV viral load results
Time frame: Each month for up to six months
Mean Time Clients Spend in Clinic
Impact on routine ART Clinic flow
Time frame: Each clinic day for up to 9 months
Provider Perception of Workload
Perceived time spent conducting on-site testing vs send-out testing
Time frame: Pre- and post-intervention (approximately 6 months apart)
Mean and median time-to-result
Mean and median number of days from blood draw to client receiving viral load result either from current standard of care or on-site testing
Time frame: Up to 90 days after blood draw, after which considered not returned
Machine Down-Time and Maintenance
Total number of hours spent in maintenance, trouble-shooting, or repair
Time frame: Each clinic day (i.e. weekly) during the 6 months of Phase 2 when the Xpert is operational
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.